Main Catalog

Found 75
Sort By
Nexus 2019
Member Free
Non-Member $30.00

Preventative Treatment for Alzheimer’s Disease and the Future Role of Value-Based Payment Arrangements

Contact Hours: 1.5. The current understanding of Alzheimer’s disease is evolving.
Value-Based Contracting Alzheimer's
Nexus 2020 Virtual
Member $15.00
Non-Member $30.00

Federal and State Legislative and Regulatory Update Home Study Nexus 2020

Contact Hours: 1 - In today’s world there are many uncertainties, especially with the COVID-19 pandemic, but health care legislation and regulation continue to move at a staggering pace.
Legislation
Nexus 2020 Virtual
Member $15.00
Non-Member $30.00

Keeping Up with Rare Disease Therapies: Pipeline to Management Solutions Track

Contact Hours: 1 - Over the last several years, payers have increased their focus on the management of rare diseases.
Drug Pipeline Rare Diseases
Nexus 2020 Virtual
Member $15.00
Non-Member $30.00

Value-Based Payment Models: Opportunities to Integrate Pharmacists from a Variety of Practice Settings

Contact Hours: 1 - Shared savings plans can mitigate health care costs, but how do we establish the relationships required for their success?
Value-Based Contracting
Nexus 2020 Virtual
Member $15.00
Non-Member $30.00

The Role of Health Disparities and Social Determinants of Health in Promoting Health and Health Equity

Contact Hours: 1 - Health care disparities are often viewed through the lens of race/ethnicity and socioeconomic status.
Health Disparities Social Determinants
Nexus 2020 Virtual
Member $15.00
Non-Member $30.00

Keeping Up with State Legislators: Legislative Updates and Outlook

Contact Hours: 1 - The COVID-19 pandemic had a significant impact on state legislation and regulation.
Legislation
Nexus 2020 Virtual
Member $15.00
Non-Member $30.00

How is Real-World Evidence in Oncology Used by Payers in Decision-Making? Home Study

Contact Hours: 1 - Payers face significant and growing costs with oncology treatments.
Oncology Real World Evidence
Nexus 2019
Member Free
Non-Member $30.00

Biosimilars in the United States: Barriers, Solutions, Real-World Evidence, and the Experience of One Health System

Contact Hours: 1.5. As of July 2019, the U.S. Food and Drug Administration (FDA) had approved 25 biosimilar or follow-on biologic products.
Real World Evidence Biosimilars
eLearning Days 2021
Member Free
Non-Member $50.00

Addressing Equity in the Management of COVID-19: A Managed Care Perspective

This webcast is a recording from AMCP eLearning Days 2021.
Equity Covid-19
Journal CPE
Member Free
Non-Member Free

Navigating Changes in Clostridioides difficile Prevention and Treatment- Journal Supplement

Clostridioides difficile (C. diff, previously known as Clostridium difficile) infections are a major health care concern. This journal CPE activity offers 1.5 CPE.
C. Diff